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Background: Chronic myeloid leukemia (CML) is genetically characterized by the occurrence of a reciprocal
translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22, i.e. the
Philadelphia (Ph) chromosome. During CML progression 60–80% of the cases acquire additional genetic changes.
Even though hyperdiploidy is not a rare finding in advanced phase-CML, hyperdiploidy together with a T315I kinase
domain (KD) mutation in the BCR-ABL gene has not yet been reported.
Results: A complete cytogenetic and molecular cytogenetic analysis; molecular biology methods such as
quantitative reverse transcription polymerase chain reaction (RQ-PCR) and allele-specific oligonucleotide (ASO)-PCR;
and immunophenotypically confirmed CML in acceleration phase (AP). Our case revealed the presence of hyperdiploidy
including multiple copies of the Ph chromosome, presence of b3a2 fusion transcript,T315I mutation in BCR-ABL KD in
pre imatinib mesylate (IM) treatment. The ratio of BCR-ABL/ABL expression in post nilotinib treatment was 0.07% on
international scale.
Conclusions: The patient demonstrated a good response to nilotinib after imatinib failure; while the
hyperdiploid clone disappeared the T315I mutation remained during follow-up. The underlying mechanisms
and prognostic implications of these cytogenetic abnormalities are discussed.
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Chronic myeloid leukemia (CML) is a disorder charac-
terized by the formation of granulocytes in connection
with a translocation involving chromosomes 9 and 22.
Resulting derivative chromosome 22 is called Philadel-
phia chromosome (Ph) [1]. A simple reciprocal trans-
location of t(9;22)(q34;q11) can be observed as single
aberration in the early stage chronic phase (CP) whereas
in most advanced cases this change is accompanied by
other chromosomal aberrations. In fact, a chimeric gene
BCR-ABL gene and protein is formed. The fused gene
has an oncogenic activity and encodes for an active tyro-
sine kinase [2]. Hyperdiploidy is not common in CML* Correspondence: ascientific@aec.org.sy
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unless otherwise stated.cases [3] and it is a common finding in advanced phase-
CML patients [4,5] and it was already in one CML-CP
patient as a secondary chromosomal aberration after
imatinib mesylate (IM) therapy [6].
Imatinib (IM = Glivec, formerly STI571) is a chem-
ically designed drug which blocks BCR/ABL1 tyrosine
kinase activity and is successfully used in CML patients
[7]. Nilotinib is a second generation tyrosine kinase inhi-
biter (TKI) with improved target specificity and potency.
Nilotinib acts like IM and binds to the kinase domain
(KD) of ABL1. This prevents the formation of an active
conformation, catalyzing the transduction of the BCR-ABL
signal [8]. Nilotinib was approved for CML treatment in
CP and AP especially in cases showing IM resistance due
to mutations in BCR-ABL tyrosine kinase geneor intoler-
ance to prior successful IM therapy [9,10]. T315I is one ofral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has been associated with TKI resistance of 1st and 2nd
generation drugs [11].
Here we presented a new CML case in AP pre IM
treatment with hyperdiploidy including more than one
copy of the Ph chromosome, presence of b3a2 fusion
transcript, a T315I mutation in the BCR-ABL KD, and a
ratio of BCR-ABL/ABL1 expression post nilotinib treat-
ment was 0.07% on international scale (IS). This patient
demonstrated a good response to nilotinib after imatinib
failure.
Case presentation
In June 2012 a 53-year-old male was diagnosed as suffer-
ing from CML. Physical examination revealed hepatosple-
nomegaly, several skin nodules (2 cm) in different locations
such as neck and armpit (data not shown), anemia,
thrombocytopenia, fever, fatigue, and loss of weight were
the indicative symptoms. The patient’s hematologic
parameters were white blood cells (WBC) of 52.2x109/l
(15% of cells were blasts), red blood cell (RBC) count was
2.50x106/mm3, hemoglobin level was 7.1 g/dl and the
platelet count was 90x109/l. Serum lactate dehydrogenase
value (LDH) was 1,851 U/l (normal level <460 U/l). The
patient was diagnosed as CML-AP according to WHO
recommendations and in an intermediate Sokal risk of
0.89 (0.8-1.2). No treatment had been administered prior
to the test.
The patient was referred for a second time in November
2013 and was treated with IM (400 mg/day) for 5 months.
Thus therapeutic scheme was changed to nilotinib
(600 mg/day) for 6 months with disappeared the previous
reported relevant symptoms. The more recent hematological
parameters were: WBC 5.3x109/l (50.2% neutrophils, 48.1%
lymphocytes, 0.9% monocytes and 0.8% eosinophiles). The
platelet count was 118x109/l and the hemoglobin level
was 12.4 g/dl.Figure 1 GTG-banding revealed a hyperdiploid karyotype. All derivativResults




tinib treatment banding cytogenetics revealed a karyotype
of 46,XY,t(9;22)[1]/46,XY[39] (Figure 1). Further studies were
done based on molecular cytogenetics (Figure 2) and mo-
lecular genetics (Figure 3). Dual-color-FISH pre IM treat-
ment; using a specific probe for BCR and ABL1 revealed
onefusion signal on the derivative chromosomes 9 [der(9)]
and another three fusion signals on the up to three Ph chro-
mosomes (Figure 2); and chromosomes 3, 6, 7, 8, 9, 10, 12,
15, 19 and 22, were studied with WCP and/or CEP probes
and did not provide any hint on cryptic translocations (data
not shown). RT-PCR pre IM treatment and post nilotinib
treatment confirmed the presence of the BCR-ABL1 fusion
(b3a2 transcript) revealing a major M-BCR transcript (data
not shown). RQ-PCR post nilotinib treatment demonstrated
a ratio of BCR-ABL/ABL1 expression of 0.07% on IS (data
not shown). ASO-PCR pre IM treatment and post nilotinib
treatment results showed the presence of the T315I mutation
(Figure 3, (Figure 4). The final karyotype pre IM treatment
and post nilotinib treatment was determined:




[8], and post nilotinib treatment: 46,XY,t(9;22)(q34;q11.2)
[1]/46,XY[39].
The abnormal cell population (~19% blasts in peripheral
blood specimen) showed the following immunophenotype,
which was consistent with CML-AP (WHO recommenda-
tions): CD45+, CD34+, CD10+, CD19−, CD20−, CD22−,
CD5− and CD7−, HLADr−, CD33+, CD32+, CD16−,
CD117−, CD14−, CD15−, CD64− and expressed CD11c,
CD38, CD235a and CD13 heterogeneously.e chromosomes are shown and with arrow.
Figure 2 Partial metaphase FISH using probes for BCR (green)
and ABL (red) showed 4 copies of BCR/ABL in this case, three
copies on Ph chromosome and one on der(9). Abbreviations:
# = chromosome; der = derivative chromosome.
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Presence of multiple copies of the Ph chromosome is one
of several types of IM resistance mechanisms [12,13].
According to the literature, there are a few near triploid
karyotypes reported in advanced phase-CML [14,15].
Stagno et al. [2] found a CML case in blast phase with
hyperdiploidy and it includes 10% mutant clones with
V256G mutation in BCR-ABL domain and e13a2 BCR-
ABL transcript. In this paper, we described a new CML
case in AP with hyperdiploidy including multiple copies of
Ph chromosome, presence of b3a2 fusion transcript and
T315I mutation in the BCR-ABL KD. To the best of our
knowledge, these chromosomal abnormalities, particularly
hyperdiploidy associated with T315I mutation have not
been previously observed in CML [16].
Approximately 10% of CML patients present in ad-
vanced phases called CML-AP or blast crisis (CML-BC),Figure 3 ASO-PCR monitoring and corresponding sensitivity test for d
genomic DNA obtained from healthy donor and our patient. Line M, 1 kb D
primers; P, our patient; lines 11–18 ASO-PCR T315I mutated primers; and P*without a clinically evident CP [17]. Even with the
advent of TKI therapy, the phase of disease remains an
important prognostic factor in CML [18,19].
Disease progression is uncommon currently in CML
patients treated in CP with TKI. When it occurs, pro-
gression usually occurs early during treatment. 3.3%
of CML-CP patients progressed to CML-AP/CML-BC
within the first 18 months of therapy, while <1% pro-
gressed after 4 years of therapy [20]. The criteria for
CML-AP in patients progressing on TKI therapy are
still poorly defined and disease progression in CML is
currently defined more practically in terms of respon-
siveness to TKI therapy [16].
The progression to advanced phases of disease is
caused by the development of genetic lesions in addition
to BCR-ABL; secondary cytogenetic changes are identified
in 50-80% of CML- BC cases [21]. Also this phenomenon
was described in 5-10% of patients presenting with CML-
CP and in 30% of patients developing AP features, and
has overall been associated with poor prognosis [22,23].
Cytogenetic clonal evolution was subsequently considered
as one of the factors defining CML-AP [24].
The most common mechanism of secondary resistance
to TKI is mutation in the KD of BCR-ABL. These KD
mutations develop as a result of selection pressure and
correlate with progression to advanced phases and short-
ened survival. Thus, early identification of IM resistance
is critical to allow the use of other, potentially effective
therapies, such as second generation TKI and/or stem
cell transplantation [25].
The mutation at amino acid 315 in the imatinib-
binding site (T315I mutation) confers resistance to ima-
tinib, dasatnib, and nilotinib by preventing access of
these drugs to the ATP-binding pocket [26-28]. Hughes
et al. [29] found six cases (5 IM resistant and one IM in-
tolerant, i.e. six in total) with T315I mutation and two of
the six cases did not showed responses to Nilotinib but
couldn’t sustain. In addition, Jabbour et al. [30] foundetected T315I mutation pre-IM treatment. ASO-PCR products on
NA ladder; lines 1,2 blank; lines 3–10 patients ASO-PCR T315I wild-type
, our patient with T315I mutation.
Figure 4 ASO-PCR monitoring and corresponding sensitivity test for detected T315I mutation Post-nilotinib treatment. Line M, 1 kb
DNA ladder; lines 1–8 patients ASO-PCR T315I wild-type primers; P, our patient; lines 9–16 ASO-PCR T315I mutated primers; and P*, our patient
with T315I mutation.
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cytogenetic response to Nilotinib. Also, Jabbour et al.
[31] found of CML-AP with T315I mutation and Niloti-
nib resistance. However, T315I mutation also was observed
in 10 cases post IM failure (4 CP, 5 AP, and 1 blast phase)
and 2 cases post Nilotinib treatment in the study by
Cortes et al. [32]. Cea et al. [33] also found T315I muta-
tion post IM, post Nilotinib and during Dasatinib treat-
ment in e19a2 BCR/ABL1 CML. Our patient achieved a
major cytogenetic response and major molecular response
after 6 months of nilotinib treatment with T315I mutation
remaining.
The mechanisms by which these mutations develop
are poorly understood. KD mutations can be present at
low-levels in CML cases prior to exposure to TKI therapy.
However, these small mutant clones do not necessarily
confer an adverse prognosis and resistant clones may not
expand even under the selection pressure of TKI therapy
[34,35]. The KD mutations usually occur within the first
2 years of TKI therapy and are much more common in
CML-AP and CML-BC than CML-CP [7].
In conclusion, we described a new CML case in AP
pre IM treatment with hyperdiploidy including multiple
copies of Ph chromosome, and presence of T315I muta-
tion in the BCR-ABL KD. The patient demonstrated a
good response to nilotinib treatment after imatinib
course failure. Interestingly hyperdiploidy clone disap-
peared while the T315I mutation remained.Materials and methods
Chromosome analysis
Chromosome analysis applying GTG-banding according
to standard procedures [36] was performed pre IM treat-
ment and post nilotinib treatment. 20 metaphase cells
derived from unstimulated bone marrow culture were
analyzed. Karyotypes were described according to the
International System for Human Cytogenetic Nomencla-
ture (ISCN 2009).Molecular cytogenetics
Fluorescence in situ hybridization (FISH) using the LSI
BCR/ABL dual color dual fusion translocation probe
(Abbott Molecular/Vysis, Des Plaines, IL, USA) and/or
chromosome enumeration probes (CEP) for chromosomes
6, 7, 8 and/or 12 (Abbott Molecular/Vysis, Des Plaines, IL,
USA) were applied together with whole chromosome
painting (WCP) probes for chromosomes 3, 9, 10, 15, 19
and/or 22 (MetaSystems, Altlussheim, Germany) according
to manufacturer’s instructions [36]. A minimum of 10
metaphase spreads was analyzed, using a fluorescence
microscope (AxioImager.Z1 mot, Carl Zeiss Ltd., Hertford-
shir, UK) equipped with appropriate filter sets to discrimin-
ate between a maximum of five fluorochromes plus the
counterstain DAPI (4′,6- diamino-2-phenylindole). Image
capture and processing were performed using an ISIS
imaging system (MetaSystems, Altlussheim, Germany).Reverse transcriptase-polymerase chain reaction (RT-PCR)
and quantitative reverse transcription polymerase chain
reaction (RQ-PCR) for BCR/ABL1 fusion transcripts
Total RNA extracted from peripheral blood sample using
the InviTrap RNA kit (Invitek, Berlin, Germany) according
to the manufacturer’s recommendations. cDNA was pre-
pared from 5 μg of total RNA with the Genequality BCR-
ABL1 kit (AB Analitica, Padova, Italy) and BCR-ABL1
fusion transcript was performed according to the manu-
facturer’s instructions (AB Analitica, Padova, Italy). RQ-
PCR analyses were performed in StepOne Real-Time
PCR (Applied Biosystems, Foster City, California, USA)
using one-step qRT-PCR BCR-ABL1 kit (MolecularMD,
Portland, USA) according to the manufacturer’s
recommendations.Allele-specific oligonucleotide (ASO)-PCR
Mutated or wild-type sequences were amplified in a
noncompetitive PCR reaction performed on genomic
DNA and PCR conditions using allele-specific and
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previously. The length of the PCR product using 1 Kb
DNA ladder (Fermentas, Lithuania, Vilnius) was (158 bp).
The sensitivity of this assay was determined for each
mutation by amplification of 10-fold limited dilutions of
100 ng patient’s DNA at time of resistance in 100 ng
healthy control DNA [37].
Flow cytometricimmunophenotype
Flow cytometry of leukemic blasts was performed using
a general panel of fluorescent antibodies against the fol-
lowing antigens typical for different cell lineages and cell
types: CD1a, CD2, CD3, CD4, CD5, CD8, CD10, CD11b,
CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22,
CD23, CD32, CD33, CD34, CD38, CD41a, CD45, CD56,
CD57, CD64, CD103, CD117, CD123, CD209, CD235a
and CD243; in addition antibodies against Kappa and
Lambda light Chains, sIgD, sIgM, and HLADr were ap-
plied (BD Biosciences). Four-color immunophenotyping
on peripheral blood specimen was performed. Samples
were stained and analyzed on a BD FACSCalibur™ flow cyt-
ometer according to BD Biosciences manuals and products
insert sheets. Autofluorescence, viability, and isotype con-
trols were included. Flow cytometric data acquisition and
analysis were conducted by BD Cellquest™ Pro software.
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